Pneumocystis jirovecii Pneumonia
- PMID: 29493992
- Bookshelf ID: NBK482370
Pneumocystis jirovecii Pneumonia
Excerpt
Pneumocystis carinii pneumonia (PCP), now referred to as Pneumocystis jirovecii pneumonia, is a fungal infection that most commonly affects the immunocompromised and, in some cases, can be severely life-threatening (see Image. Pneumocystis Carinii Pneumonia). Typically, patients at risk are those with underlying disease states that alter host immunity, such as cancer, human immunodeficiency virus (HIV), transplant recipients, or those taking immunosuppressive therapies and medications. Patients presenting with PCP may show signs of fever, cough, dyspnea, and, in severe cases, respiratory failure.
Pneumocystis is thought to be transmitted from person to person through an airborne route. Asymptomatic lung colonization can occur in people with normal immune systems, and they may unknowingly become reservoirs (asymptomatic carriers) for the spread of Pneumocystis to immunocompromised individuals. Although it is still the most common and serious opportunistic respiratory infection in patients with acquired immunodeficiency syndrome [AIDS]), thanks to the widespread use of prophylaxis and antiretroviral therapy, the incidence of infection in this population has declined substantially.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
- Continuing Education Activity
- Introduction
- Etiology
- Epidemiology
- Pathophysiology
- Histopathology
- History and Physical
- Evaluation
- Treatment / Management
- Differential Diagnosis
- Prognosis
- Complications
- Consultations
- Deterrence and Patient Education
- Pearls and Other Issues
- Enhancing Healthcare Team Outcomes
- Review Questions
- References
References
-
- Ricciardi A, Gentilotti E, Coppola L, Maffongelli G, Cerva C, Malagnino V, Mari A, Di Veroli A, Berrilli F, Apice F, Toschi N, Di Cave D, Parisi SG, Andreoni M, Sarmati L. Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients. PLoS One. 2017;12(5):e0176881. - PMC - PubMed
-
- Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol. 2017 Jul-Aug;35(4):671-673. - PubMed
-
- Amber KT. Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions". Int J Dermatol. 2017 Jan;56(1):e4-e5. - PubMed
-
- Fillâtre P, Revest M, Belaz S, Robert-Gangneux F, Zahar JR, Roblot F, Tattevin P. [Pneumocystosis in non-HIV-infected immunocompromised patients]. Rev Med Interne. 2016 May;37(5):327-36. - PubMed
-
- Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, Rolston KV, Raad II, Kontoyiannis DP. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006 Jun;25(6):382-8. - PubMed
Publication types
LinkOut - more resources
Full Text Sources